Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its sustained-delivery hydrogel technologies to support both internally developed assets and external pharma collaborations.
Michael O'Rurke
Advertisement
Articles by Michael O'Rurke
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5